Heritage Cited by FDA for Omitting Adverse Events

Drug GMP Report
A A
Heritage Pharmaceuticals has been hit with a warning letter for what the FDA calls “serious violations” of postmarket reporting requirements.

To View This Article:

Login

Subscribe To Drug GMP Report